Mode
Text Size
Log in / Sign up

Narrative review links myasthenia gravis and autoimmune encephalitis riskMG and Brain Inflammation Linked in New Review

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider the reported association between myasthenia gravis and autoimmune encephalitis when evaluating patients.

This narrative review explores the relationship between myasthenia gravis and autoimmune encephalitis, drawing on epidemiological data and multiple single case reports. The authors illustrate an increased risk for autoimmune encephalitis in patients with myasthenia gravis. The review does not provide pooled effect sizes, as it is not a meta-analysis.

The authors discuss treatment approaches for both conditions. For myasthenia gravis, they state that active treatment with immunosuppression should follow updated and generally accepted guidelines. For autoimmune encephalitis, they suggest considering high corticosteroid doses, intravenous immunoglobulin, plasma exchange, rituximab, and FcRn-blockers.

Key limitations include the narrative nature of the review and the absence of a systematic search or formal quality assessment. The authors do not report a study population, sample size, or specific statistical results. The evidence base is primarily illustrative rather than quantitative.

Practice relevance is limited to the authors' synthesized recommendations. Clinicians should be aware of the potential association but recognize the lack of robust trial-level data. The suggested treatments should be considered in the context of individual patient assessment and established guidelines.

  • MG patients face higher risk of brain inflammation
  • Could help explain confusion, memory issues in some
  • Not a new treatment — but changes how we treat

This review reveals that myasthenia gravis is often linked to brain inflammation — and that may change how doctors treat tough cases.

You wake up tired, your eyelids droop, and your muscles feel weak. That’s normal for someone with myasthenia gravis (MG). But then, one day, you start forgetting words. You feel confused. You can’t focus.

Doctors might have brushed it off as stress. But what if it’s not? What if the disease attacking your muscles is also attacking your brain?

MG affects about 20 out of every 100,000 people. It weakens the signals between nerves and muscles. People with MG may struggle to speak, swallow, or even breathe.

Most treatments focus on the body — not the brain. But some patients have symptoms that don’t add up. Memory lapses. Hallucinations. Seizures.

Now, experts say these could be signs of something more: autoimmune encephalitis. That’s when the immune system attacks the brain.

And it may be more common in MG patients than we thought.

The Hidden Connection

For years, doctors saw MG and brain inflammation as separate problems. If a patient had both, they assumed it was just bad luck.

But this new review says: it’s not random.

MG and autoimmune encephalitis are both caused by rogue antibodies — the immune system’s attack tools gone wrong.

In MG, those antibodies attack the nerve-muscle connection. It’s like cutting the wires between a switch and a light.

But here’s the twist: some of those same faulty antibodies may also target the brain.

Two Attacks, One Immune System

Think of your immune system like a security team. Normally, it protects you. But in autoimmune diseases, it starts attacking your own cells.

In MG, it attacks the “lock” where nerves tell muscles to move.

In autoimmune encephalitis, it attacks the brain’s “traffic signals” — the parts that help brain cells talk to each other.

Some patients have antibodies that can target both.

It’s like a faulty key that fits two locks — one in the muscle, one in the brain.

What They Didn’t Expect

The review looked at past cases and studies. It found that people with MG are more likely to develop autoimmune encephalitis than the general population.

And it’s not just one type of antibody. Some patients had anti-AChR antibodies (common in MG). Others had anti-LGI1, anti-CASPR2, or anti-NMDAR — usually linked to brain inflammation.

Some even had both at once.

Surprising Symptoms Explained

One patient had classic MG: drooping eyes, weak limbs. Then, suddenly, he started having memory blackouts.

Another woman with MG began hallucinating and became aggressive. Brain scans showed inflammation.

Once doctors treated the brain inflammation, her mind cleared — but her muscle weakness stayed.

This means: treating only the muscles may not be enough.

This doesn’t mean this treatment is available yet.

But There’s a Catch

Not every MG patient will get brain inflammation.

And not every strange mental symptom means encephalitis.

But doctors now need to watch for red flags:

  • Sudden confusion
  • Memory loss
  • Seizures
  • Personality changes

These could mean the immune attack has spread to the brain.

How Doctors Should Respond

The review says: treat both conditions early and aggressively.

For MG, standard care includes steroids, IVIg (infused antibodies), or plasma exchange (cleaning the blood).

For autoimmune encephalitis, the same tools are used — plus drugs like rituximab, which resets part of the immune system.

Newer drugs, like FcRn blockers (which help remove harmful antibodies), may help both conditions.

The key is: treat the whole patient — not just the muscles.

Why This Changes Things

We used to think MG only affected the body.

Now, we see it may be part of a broader immune problem.

This could explain why some patients don’t improve with standard MG treatment.

Their brain may be under attack too.

If you or a loved one has MG and new mental symptoms, speak up.

Tell your doctor if you’re confused, forgetful, or acting differently.

Ask: “Could this be more than MG?”

It’s not about scaring you — it’s about getting the right care.

Not All Cases Are the Same

The review is based on case reports and small studies.

It doesn’t prove that all MG patients need brain scans.

And not every mental symptom means encephalitis.

But it does show a clear pattern that doctors can no longer ignore.

More research is needed to find out how often this happens — and who’s most at risk.

Doctors may soon test MG patients for brain-targeting antibodies, even without symptoms.

For now, the message is clear: when MG acts strange, look beyond the muscles.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
ObjectiveThis review aims to provide updated information about myasthenia gravis (MG) complicated with autoimmune encephalitis.BackgroundMG and autoimmune encephalitis are both antibody-mediated disorders with a need for active and individually adapted immunosuppressive treatment. The two disorders can co-exist. This represents therapeutic and diagnostic challenges but may help in elucidating disease mechanisms and risk factors.MethodsA literature search combined the words “myasthenia gravis,” “autoimmune encephalitis,” and further combined each specific antibody associated with autoimmune encephalitis and “myasthenia gravis.”ResultsEpidemiological data and multiple single case reports illustrate the increased risk for autoimmune encephalitis in MG. The target antigens for the antibodies in both MG and autoimmune encephalitis vary among patients. Clinical manifestations, choice of therapy, and prognosis depend on antibody pattern. MG should be treated actively with immunosuppression according to updated and generally accepted guidelines. For treatment of autoimmune encephalitis, high corticosteroid doses, intravenous immunoglobulin (IVIg), plasma exchange, and rituximab should be considered. FcRn-blockers represent an additional option.ConclusionMG and autoimmune encephalitis have overlapping pathogenesis and similar preferred drug therapies. This comorbidity represents a therapeutic challenge, and often with the need of high-dose immunosuppressive combination therapy. New and targeted therapies are applied in some MG patients, and such therapies have relevance also for autoimmune encephalitis.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.